August 7th, 2009
The Southern Australian biotech company: Vaxine Pty. Ltd., will be the first to administer a human swine flu vaccine immunization.
Vaxine’s Research Director Prof. Nikolai Petrovsky boasted that their virus vaccine, unlike traditional old-fashioned egg-based vaccines, “is based on state-of-the-art recombinant protein technology combined with our proprietary polysaccharide adjuvant system.”
Thanks to Petrovsky’s collaboration with clinical investigator Dr. Dimitar Sajkov, their swine flu vaccine possesses a contemporary design, which permits the vaccine to be produced much more quickly, making it an ideal candidate for rapid vaccine production in pandemic situations.
The vaccine took a mere three months to develop and produce, and if this study is successful, it could mean the end of old-fashioned egg-based vaccines. To deviate from the outdated version of vaccine production, would eliminate viral contaminants and would be a safe alternative for people with egg allergies.
Vaxine has applied their ADVAX adjuvant to the vaccine which provides intense influenza protection, thanks to anti-influenza antibodies and T-cells (central defense agents of the body’s defense against the influenza virus).
Clinical trials of the swine flu vaccine will coordinated by Finders Medical Center and will be administered on 300 healthy candidates aged 18 – 70.
